The PennZone

  • Home
  • Business
  • Health
  • Financial
  • Education
  • Entertainment
  • Legal
  • Construction
  • Non-profit

Juventix Regenerative Medical Announces Strategic Partnership with Juvasonic® to Expand Needle-Free Biologic Delivery Platform
The PennZone/10305658

Trending...
  • DimHum Launches Revolutionary CrowdShipping Service
  • Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
Juvasonic Joins Juventix Aesthetic Product Lineup Juventix Regenerative Medical, LLC
Revolutionary sonic-based transdermal system joins Juventix's lineup of non-invasive and minimally invasive PRP and biologics delivery solutions, offering safe and effective access to regenerative therapies for a broader range of providers.

TAMPA, Fla. - PennZone -- Juventix Regenerative Medical, a national leader in regenerative medicine innovation, today announced a strategic corporate partnership with Juvasonic®, an FDA-cleared, needle-free delivery device designed to enhance the transdermal absorption of platelet-rich plasma (PRP), exosomes, peptides, and other advanced biologics. This partnership marks a pivotal expansion of the Juventix product portfolio and further cements the company's role as a driving force behind safe, compliant, and patient-friendly regenerative solutions.

Introducing Juvasonic®: Needle-Free, Painless, Proven

The Juvasonic® system uses high-frequency sonic vibration to temporarily disrupt the skin barrier (stratum corneum), enabling topical penetration of biologics without the use of needles or invasive techniques. Its sterile, single-use cartridges and physician-validated design ensure that providers across a spectrum of disciplines, from aesthetic medicine to integrative health, can administer regenerative therapies effectively, painlessly, and safely.

Key Features:
  • FDA-cleared and patent-pending
  • Delivers PRP, peptides, exosomes, and growth factors transdermally
  • Promotes complete skin barrier recovery within 15 minutes
  • Effective for treating delicate areas (lips, under eyes, décolletage)
  • Scientifically supported for the dissipation of filler nodules

🔗 Now available through Juventix: https://juventix.com/shop/juvasonic-transdermal-delivery-device/

More on The PennZone
  • Sci-Fi Novel from Pittsburgh Author Explores Love, Power, & Humanity in an Age of Artificial People
  • Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
  • Greenlight Networks to Acquire Loop Internet
  • Finding the Best AC Repair Service in Philadelphia
  • Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros

🎁 Introductory Offer: Use code Juvasonic® 200 at checkout for $200 OFF for a limited time.

A Fully Integrated Delivery Ecosystem for Regenerative Providers

With the addition of Juvasonic®, Juventix now offers one of the most comprehensive regenerative biologic delivery platforms available designed for safe use by MDs, DOs, nurses, chiropractors (DCs), naturopathic doctors (NDs), and medical aestheticians alike.

Juventix's Needle-Free & Minimally Invasive Portfolio Includes:

🔹 NanoPen Pro
FDA-cleared microneedling system that enhances PRP absorption and collagen stimulation with precise depth control.
→ www.nanopen.pro

🔹 Apollo Duet
Dual-mode RF and cryo technology platform that drives biologics transdermally while rejuvenating the skin with thermal modulation.
→ Device Overview

🔹 PRiVIVE® Peptide Serum
Formulated for enhanced topical PRP absorption, this transdermal serum supports cellular hydration, healing, and post-procedural outcomes.
→ PRiVIVE® on Juventix

Together, these systems give clinics, wellness centers, and aesthetic practices a turnkey solution to deliver regenerative care across a variety of clinical applications:
  • Facial Rejuvenation
  • Hair Restoration
  • Dermal Filler Nodule Dissipation
  • Skin Texture & Tone Improvement
  • Pain-Free Biologic Treatment for Needle-Averse Patients

Expanding Clinical Access and Empowering Providers

More on The PennZone
  • BIYA Forecasts 2025 Surge with ¥300M ($41.8 M USD) in Revenue and ¥25M Profit from Cloud Based HR Solutions: Baiya Intl. Group (N A S D A Q: BIYA)
  • Paul E. Saperstein Co. Announces Geographic Expansion of Auction Services
  • Florida Broker Bent Danholm Featured in the Daily Mail's U.S. Real Estate Coverage
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • Melissa B. Releases Digitally Independent: Empowering Music Artists with AI and Brand Strategy

This collaboration between Juventix and Juvasonic® represents more than a new product; it represents a clinical opportunity. Many practitioners outside of traditional MD and DO scopes of practice are limited in their ability to offer injectable regenerative therapies due to training, licensing, or patient preference. Juvasonic® and the Juventix delivery platform enable these providers to:
  • Expand treatment offerings safely and legally
  • Increase cash-based revenue streams
  • Deliver clinically validated outcomes using trusted regenerative inputs

Quote from Juventix CEO Lance Liberti:

"We believe that regenerative medicine should be accessible to every qualified healthcare provider and every patient who can benefit from it. Our partnership with Juvasonic® is a major step in making this vision a reality, delivering effective biologics without needles, discomfort, or regulatory complexity."

About Juventix Regenerative Medical

Juventix Regenerative Medical is a leader in regenerative therapies, specializing in the distribution of high-quality PRP kits, peptide serums, exosomes, and advanced biologic delivery systems. With a commitment to scientific integrity, provider support, and patient-centered outcomes, Juventix offers a full ecosystem for regenerative medicine professionals.

🔗 Website: www.juventix.com
📍 Headquarters: Tampa, FL
📞 Sales & Support: 866-693-4777
📧 Media Inquiries: hello@juventix.com

RESTORE, REVIVE, REGENERATE — JUVENTIX REGENERATIVE MEDICAL

Contact
Lance Liberti
CEO & Founder
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical LLC
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Germantown Fashion & Arts Festival 2025 Draws Thousands, Celebrates Creativity in Historic Philly
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative
  • Casting Pro Darya Balyura Named Judge for 2025 Meals 4 Monologues Virtual Showcase
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter
  • Drone Light Shows Emerge as the New Standard in Live Event Entertainment
  • Lore Link is Here to Help Organize Your Game
  • Chappaqua's Annual Townwide Summer Sale – Unbeatable Savings at Your Favorite Local Boutiques!
  • Skyline Partners with ZenSpace to Offer Private Meeting Pods for Trade Show Exhibitors
  • VIP Vacations Honored as One of the Top 25 Group Accounts for Classic Vacations for 2024
  • DICK'S Sporting Goods Announces DICK'S Deal Days, a Four-Day Summer Savings Event
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Construcción del Corredor Norte–Sur (NSC) de Singapur
  • New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
  • Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce

Popular on PennZone

  • Let's Talk Series: At the Crossroads: Immigration Today
  • INVESTIGATION ALERT: Berger Montague PC Investigates Coinbase Global, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NASDAQ: COIN)
  • Innovative EDM Music Project, "Terms of War," Depicts an A.I. Takeover of Earth
  • Behavioral Health Advocates to Hold Joint Capitol Hill Press Conference on June 11
  • Kemeny, Ramp & Renaud Expands Legal Team with Attorney Baruch Kraut
  • LIB Continuous Innovation: Custom Rain Test Chambers & IP Labs
  • New Bethany Acquires Former Diocesan Headquarters to Expand Services
  • Bethany Nikitenko Honored By Legal Intelligencer with Power Player Award
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement

Similar on PennZone

  • Affordable, High-Quality Care: Cheap Braces for Adults Available from Exeter Smiles in Reading
  • NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
  • Robin Launches Legal Intelligence Platform to solve intelligence gap in Fortune 500 legal teams
  • e4health Earns 2025-2026 Great Place To Work Certification™ for Fourth Consecutive Year
  • Deaths Spur Closures, but Troubled Teen Camps Must Be Banned, CCHR Warns
  • SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us